Tenax Therapeutics activates first clinical research site for phase 2 trial for PH-HFpEF
Tenax Therapeutics announced that Stanford University School of Medicine has been activated as the first clinical research site for the Company’s Phase 2 trial designed to evaluate levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction. November 19, 2018